COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period

Paxlovid was authorized by FDA to treat mild-to-moderate COVID-19. In May 2022, the Centers for Disease Control and Prevention (CDC) issued a Health Alert Network Health Advisory on potential COVID-19 rebound after Paxlovid treatment. Since June 2022, Omicron BA.5 has become the dominant subvariant...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lindsey, Volkow, Nora D., Davis, Pamela B., Berger, Nathan A., Kaelber, David C., Xu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387159/
https://www.ncbi.nlm.nih.gov/pubmed/35982673
http://dx.doi.org/10.1101/2022.08.04.22278450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387159/
https://www.ncbi.nlm.nih.gov/pubmed/35982673
http://dx.doi.org/10.1101/2022.08.04.22278450

Ejemplares similares